VXRT Overview

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.

Wall Street analysts forecast VXRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VXRT is6.00 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Vaxart Inc revenue for the last quarter amounts to 20.88M USD, increased 857.18

Vaxart Inc. EPS for the last quarter amounts to -0.07 USD, decreased -50.00

Vaxart Inc (VXRT) has 105 emplpoyees as of May 18 2026.

Today VXRT has the market capitalization of 118.17M USD.